PURPOSE: Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120 hours). Therefore, recommended antiemetic regimens include multiple-day NK1RA administration. Preliminary data suggested that single-dose aprepitant before chemotherapy could provide CINV protection throughout the overall risk phase (OP; 0 to 120 hours). This study compared a 3-day oral aprepitant schedule to a regimen containing a single dose of the intravenous NK1RA fosaprepitant. PATIENTS AND METHODS: A randomized, double-blind, active-control design was used to test whether fosaprepitant is noninferior to aprepitant. Patients receiving cisplatin ≥ 70 mg/m(2) for the first time received ondansetron and dexamethasone with a standard aprepitant regimen (125 mg on day 1, 80 mg on day 2, 80 mg on day 3) or a single-dose fosaprepitant regimen (150 mg on day 1). The primary end point was complete response (CR; no vomiting, no rescue medication) during OP. Secondary end points were CR during DP and no vomiting during OP. Accrual of 1,113 evaluable patients per treatment arm was planned to confirm noninferiority with expected CR of 67.7% and noninferiority margin of minus 7 percentage points. RESULTS: A total of 2,322 patients were randomly assigned, and 2,247 were evaluable for efficacy. Antiemetic protection with aprepitant and fosaprepitant was equivalent within predefined bounds for noninferiority. Both regimens were well tolerated, although more frequent infusion site pain/erythema/thrombophlebitis was seen with fosaprepitant relative to aprepitant (2.7% v 0.3%, respectively). CONCLUSION: Given with ondansetron and dexamethasone, single-dose intravenous fosaprepitant (150 mg) was noninferior to standard 3-day oral aprepitant in preventing CINV during OP and DP.
RCT Entities:
PURPOSE: Addition of aprepitant, a neurokinin-1 receptor antagonist (NK1RA), to an ondansetron and dexamethasone regimen improves prevention of chemotherapy-induced nausea/vomiting (CINV), particularly during the delayed phase (DP; 25 to 120 hours). Therefore, recommended antiemetic regimens include multiple-day NK1RA administration. Preliminary data suggested that single-dose aprepitant before chemotherapy could provide CINV protection throughout the overall risk phase (OP; 0 to 120 hours). This study compared a 3-day oral aprepitant schedule to a regimen containing a single dose of the intravenous NK1RA fosaprepitant. PATIENTS AND METHODS: A randomized, double-blind, active-control design was used to test whether fosaprepitant is noninferior to aprepitant. Patients receiving cisplatin ≥ 70 mg/m(2) for the first time received ondansetron and dexamethasone with a standard aprepitant regimen (125 mg on day 1, 80 mg on day 2, 80 mg on day 3) or a single-dose fosaprepitant regimen (150 mg on day 1). The primary end point was complete response (CR; no vomiting, no rescue medication) during OP. Secondary end points were CR during DP and no vomiting during OP. Accrual of 1,113 evaluable patients per treatment arm was planned to confirm noninferiority with expected CR of 67.7% and noninferiority margin of minus 7 percentage points. RESULTS: A total of 2,322 patients were randomly assigned, and 2,247 were evaluable for efficacy. Antiemetic protection with aprepitant and fosaprepitant was equivalent within predefined bounds for noninferiority. Both regimens were well tolerated, although more frequent infusion site pain/erythema/thrombophlebitis was seen with fosaprepitant relative to aprepitant (2.7% v 0.3%, respectively). CONCLUSION: Given with ondansetron and dexamethasone, single-dose intravenous fosaprepitant (150 mg) was noninferior to standard 3-day oral aprepitant in preventing CINV during OP and DP.
Authors: Juan Bayo; Paula J Fonseca; Susana Hernando; S Servitja; A Calvo; S Falagan; Estefanía García; Iria González; María José de Miguel; Quionia Pérez; Ana Milena; Antonio Ruiz; Agustí Barnadas Journal: Clin Transl Oncol Date: 2012-06 Impact factor: 3.405
Authors: A D Leal; K C Kadakia; S Looker; C Hilger; K Sorgatz; K Anderson; A Jacobson; D Grendahl; D Seisler; T Hobday; Charles L Loprinzi Journal: Support Care Cancer Date: 2014-01-09 Impact factor: 3.603
Authors: Jordan D Lundberg; Brooke Sorgen Crawford; Gary Phillips; Michael J Berger; Robert Wesolowski Journal: Support Care Cancer Date: 2014-01-09 Impact factor: 3.603
Authors: George Dranitsaris; Sasha Mazzarello; Stephanie Smith; Lisa Vandermeer; Nathaniel Bouganim; Mark Clemons Journal: Support Care Cancer Date: 2015-09-17 Impact factor: 3.603
Authors: Jørn Herrstedt; Fausto Roila; David Warr; Luigi Celio; Rudolph M Navari; Paul J Hesketh; Alexandre Chan; Matti S Aapro Journal: Support Care Cancer Date: 2016-07-22 Impact factor: 3.603
Authors: Livia T Hegerova; Alexis D Leal; Darryl C Grendahl; Drew K Seisler; Kristine M Sorgatz; Kari J Anderson; Crystal R Hilger; Charles L Loprinzi Journal: Support Care Cancer Date: 2014-06-26 Impact factor: 3.603